Sen. Harkin interested in FDA use of foreign marketing data to support U.S. availability.
This article was originally published in The Rose Sheet
Executive Summary
REP. HARKIN CONSIDERING LEGISLATION ON FDA USE OF FOREIGN MARKETING DATA if the agency does not change its policy on the issue. At a May 22 session of the First International Congress on Alternative and Complementary Medicine, Sen. Tom Harkin's (D-IA) Legislative Director Peter Reinecke said the senator "has been working on the issue" of FDA "prohibiting the consideration of foreign use data relative to drugs" during the "process for their review for FDA approval."